ZNTL — Zentalis Pharmaceuticals, Inc.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1725160 ·
Last close
$1.49
Market Cap
$146.42M
52W High
$6.95
52W Low
$1.28
ADV30
1,335,001
Next earnings
2026-11-10
Zentalis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers in the United States. It develops azenosertib, which is in a Phase 3 clinical trial for the treatment of ovarian cancer and other tumor types. The company also develops ZN-c3-001, a phase 1 study that evaluated azenosertib monotherapy in solid tumors; and MAMMOTH (ZN-c3-006) is a Phase 1/2 clinical trial of azenosertib in patients with PARP-inhibitor resistant ovarian cancer. It has licensing agreements and strategic collaborations with Recurium IP Holdings, LLC. Zentalis Pharmaceuticals, Inc. was incorporated in 2014 and is based in San Diego, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 0 — -31,154,000 -28,815,000 270,193,000 24,029,000 65,306,000
Jun 2026 0 — -44,391,000 -42,286,000 215,330,000 24,783,000 71,684,000
Mar 2026 0 — -37,855,000 -35,352,000 253,066,000 31,930,000 70,386,000
Dec 2025 0 — -37,393,000 -35,216,000 288,967,000 35,995,000 72,763,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$-133,839,000
Investing CF
$37,181,000
Financing CF
$81,615,000
CapEx
$-34,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.80
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,297,908,000
Inventory
—
Receivables
$0
ST Investments
$204,864,000
EBIT TTM
$-150,793,000
Pretax Income TTM
$-140,851,000
Interest Exp TTM
—
Analysts
9

Annual Trend (SEC EDGAR, last 5y)

Revenues vs Net Income (last 5y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 0 -145,012,000 -137,060,000 288,967,000 72,763,000 216,204,000 -125,247,000
Dec 2024 67,425,000 -187,458,000 -165,839,000 430,337,000 93,151,000 337,186,000 -170,860,000
Dec 2023 0 -253,941,000 -292,191,000 551,688,000 114,297,000 437,284,000 -207,822,000
Dec 2022 0 -227,287,000 -236,806,000 539,310,000 105,286,000 433,803,000 -163,751,000
Dec 2021 — — — — — — —

TTM Snapshot

Revenues TTM
$0
NetIncome TTM
$-139,545,000
OpCashFlow TTM
—
Assets (Latest)
$215,330,000
Forward EPS
$-1.52

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $2.50 · spot: $1.36 · call volume: 79 · put volume: 183

Peers — same industry

TickerNameMarket CapLastDaily %
VRXA Veraxa Biotech AG - Post de-SPAC $147.06M $1.04 —
RNA Atrium Therapeutics, Inc. $139.78M $6.48 —
ALXO ALX ONCOLOGY HOLDINGS INC $138.97M $1.00 —
SION Sionna Therapeutics, Inc. $138.87M $3.07 —
BBOT BridgeBio Oncology Therapeutics, Inc. $155.69M $1.94 —

News headlines (Yahoo Finance, 1h cache)

Zentalis Pharmaceuticals Reports Third Quarter 2026 Financial Results and Business Updates
2026-11-09 21:05 · Yahoo
Zentalis Pharmaceuticals to Participate in Upcoming Investor Conferences
2026-11-03 21:15 · Yahoo
Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-11-02 22:00 · Yahoo
Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026
2026-10-23 14:15 · Yahoo
Zentalis Pharmaceuticals Announces First Overall Survival Data for Azenosertib from DENALI Part 1b Published in ESMO Congress 2026 Abstract
2026-10-18 22:05 · Yahoo
Zentalis Pharmaceuticals Shares Rise After Leerink Assumes Coverage With Outperform Rating
2026-10-05 11:55 · Yahoo
Zentalis Pharmaceuticals Announces Closing of Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
2026-08-17 20:01 · Yahoo
Zentalis Pharmaceuticals Announces Proposed Underwritten Public Offering
2026-08-13 20:01 · Yahoo
ZNTL Stock Rises 28% in 3 Months: What's Driving the Rally?
2026-07-20 13:26 · Yahoo
Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026
2026-07-17 20:15 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.